Ann: Suspension from Official Quotation - Continued, page-162

First 162 Last

Share
Profile

Follow
Send2deking

2,431 Posts.

270

26/05/21

08:47

Post #: 53416325
Share

Originally posted by No_8 ↑

KMTW, international accounting reporting standards would not allow the disclosure of prepayments to inventory unless that inventory had actually been produced. If the inventory had been produced and held in a third party warehouse pending transit to BUD, then it would be classed as inventory. Once in transit it would be classified as such. Anything less and it would be classified as a prepayment.
Nothing would surprise me with these guys as the COO seems totally incompetent at managing and his accounting/reporting skills have been shown to be in the same category. Hopefully he is no longer employed by BUD.
I just hope BUD directors are taking their time to sort this mess out correctly and fully. Heads must roll if the company is to ever regain any credibility. Meanwhile the business will continue under inventory supply constraints. This should mean those that remain on the payroll responsible for this shambles should be wearing the cost with significant reductions in pay while the company struggles back to gain sales momentum.
In the meantime I sincerely hope BUD competitors are in a similar chip and finished goods supply constraint situation which will mean competitor product is not filling the supply void on retailer shelves due to BUD supply issues. I guess shareholders in BUD sales hot spots could readily answer this question.

Expand

BUD Price at posting: 4.3¢ Sentiment: Hold Disclosure: Held
12 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03